Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device maker Atrion (ATRI 1.27%) has earned a respected four-star ranking.
With that in mind, let's take a closer look at Atrion and see what CAPS investors are saying about the stock right now.
Atrion facts
Headquarters (founded) |
Allen, Texas (1944) |
Market Cap |
$395.8 million |
Industry |
Health care supplies |
Trailing-12-Month Revenue |
$116.1 million |
Management |
CEO David Battat (since 2011) |
Return on Equity (average, past 3 years) |
18.1% |
Cash / Debt |
$38.7 million / $0 |
Dividend Yield |
1.1% |
Competitors |
Baxter International (BAX -0.55%)Covidien (COV.DL)Teleflex (TFX 0.48%) |
On CAPS, 97% of the 257 members who have rated Atrion believe the stock will outperform the S&P 500 going forward.
Just last month, one of those bulls, fellow Fool Buck Hartzell (TMFBuck), succinctly summed up the outperform case for our community: "Great capital allocators here. Look at their returns on equity. Surprisingly diversified for a small cap company. I like the ownership and the capital allocation decisions. This is a long term hold."
If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong four-star rating, Atrion may not be your top choice.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.